Summary & Overview
HCPCS J1070: Injection, Testosterone Cypionate, up to 100 mg
HCPCS Level II code J1070 denotes an intramuscular injection of testosterone cypionate, up to 100 mg. Nationally relevant for hormone replacement therapy and related clinical uses, this supply code is used across outpatient and ambulatory care settings where parenteral medications are administered. Its utilization affects pharmacy and medical benefit billing pathways, inventory management, and provider documentation practices.
Major payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The summary covers payer coverage patterns, billing and coding considerations, and clinical context for appropriate use of testosterone cypionate injections.
Readers will learn the clinical meaning of HCPCS Level II code J1070, typical sites of service, common billing scenarios, and what to expect from national payers regarding coverage and claims handling. The publication also outlines benchmarks and policy updates relevant to injectable hormone therapies and highlights practical documentation points for claims processing. Data not available in the input where specific payer policies, modifiers, taxonomies, and ICD-10 mappings would normally be listed.
Billing Code Overview
HCPCS Level II code J1070 describes an injection of testosterone cypionate, up to 100 mg. This code represents a single administration of intramuscular testosterone cypionate intended for hormone replacement or other clinically indicated uses.
-
Service type: Parenteral medication administration (intramuscular injection)
-
Typical site of service: Outpatient clinic, physician office, or ambulatory care setting where injections are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a cisgender male or transgender male receiving intramuscular testosterone cypionate for testosterone replacement therapy. A common scenario: a 45-year-old male with documented primary hypogonadism presents to an outpatient clinic for routine hormone replacement. The clinician reviews recent labs (low morning serum total testosterone) and confirms indication. The clinic nurse prepares and administers J1070 (injection, testosterone cypionate, up to 100 mg) intramuscularly into the deltoid or gluteal muscle. Visit workflow includes verification of identity, consent for injection, medication reconciliation, allergy check, preparation of syringe, injection, brief observation for immediate adverse reaction, documentation of lot number and dose, and scheduling of follow-up and lab monitoring (testosterone levels, hematocrit). Typical administration frequency is every 1–4 weeks depending on dose and regimen. Typical sites of service are outpatient clinic, physician office, community health center, or infusion/medication administration suite; less commonly in home health if appropriate nursing services are provided.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure | Use when a distinct E/M visit is performed on same day as administration of J1070 and documentation supports separate service |